Oncology

EpimAb Biotherapeutics bags $74m amid cancer drug boom

The Shanghai-based biopharmaceutical startup is the latest to raise capital from private investors as oncology becomes one of the hottest fields in biopharma development.

EpimAb Biotherapeutics announced Wednesday that it has raised $74 million in its Series B funding, extending the streak of private fundraising among Chinese biopharmaceutical firms specialising in anti-cancer drug research.

The Shanghai-based company said the funding was co-led by SDIC Fund, the investment arm of State Development Investment Corporation, and Beijing-based venture capital firm Sherpa Healthcare Partners.

Wednesday’s announcement came slightly more than two years after EpimAb’s Series A funding round in April 2017, through which it raised $25 million from the likes of Oriza Ventures, Decheng Capital and 3E Bioventures.

The three-year-old startup is the latest in a long list of...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222